Cited by 391Ovarian cancer diagnosis and treatmentEpigenetics and DNA MethylationMetal complexes synthesis and properties

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Epigenetic Resensitization to Platinum in Ovarian Cancer

Open access

Matei, Daniela, Fang, Fang, Shen, Changyu, Schilder, Jeanne, Arnold, Alesha, Zeng, Yan, Berry, William A., Huang, Tim, Nephew, Kenneth P.·2012·Cancer Research

DOI 10.1158/0008-5472.can-11-3909PMC PMC3700422

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Preclinical studies have shown that hypomethylating agents reverse platinum resistance in ovarian cancer. In this phase II clinical trial, based upon the results of our phase I dose defining study, we tested the clinical and biologic activity of low-dose decitabine administered before carboplatin in platinum-resistant ovarian cancer patients. Among 17 patients with heavily pretreated and platinum-resistant ovarian cancer, the regimen induced a 35% objective response rate (RR) and progression-free survival (PFS) of 10.2 months, with nine patients (53%) free of progression at 6 months. Global and gene-specific DNA demethylation was achieved in peripheral blood mononuclear cells and tumors. The number of demethylated genes was greater (P < 0.05) in tumor biopsies from patients with PFS more than 6 versus less than 6 months (311 vs. 244 genes). Pathways enriched at baseline in tumors from patients with PFS more than 6 months included cytokine–cytokine receptor interactions, drug transporters, and mitogen-activated protein kinase, toll-like receptor and Jak-STAT signaling pathways, whereas those enriched in demethylated genes after decitabine treatment included pathways involved in cancer, Wnt signaling, and apoptosis (P < 0.01). Demethylation of MLH1, RASSF1A, HOXA10, and HOXA11 in tumors positively correlated with PFS (P < 0.05). Together, the results of this study suggest that low-dose decitabine altered DNA methylation of genes and cancer pathways, restoring sensitivity to carboplatin in patients with heavily pretreated ovarian cancer and resulting in a high RR and prolonged PFS. Cancer Res; 72(9); 2197–205. ©2012 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-11-3909

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108
The Epigenomics of Cancer
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
A systems biology approach for pathway level analysisPreprint
Drăghici, S., Khatri, P., Tarca, A. L., Amin, K., Done, A., Voichiţa, C., Georgescu, C., & Romero, R. J. (2007) · Genome Research · doi:10.1101/gr.6202607 · Cited by 1,263
Toll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925
Platinum Resistance: The Role of DNA Repair Pathways
Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2238 · Cited by 754
A cell biological view of Toll-like receptor function: regulation through compartmentalization
Barton, G. M., & Kagan, J. C. (2009) · Nature reviews. Immunology · doi:10.1038/nri2587 · Cited by 746
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Kantarjian, H. M., Oki, Y., Garcia‐Manero, G., Huang, X., O'Brien, S. M., Cortes, J. E., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z. E., et al. (2006) · Blood · doi:10.1182/blood-2006-05-021162 · Cited by 684
DNA methylation analysis by pyrosequencing
Tost, J., & Gut, I. G. (2007) · Nature Protocols · doi:10.1038/nprot.2007.314 · Cited by 681

Show all 56 references

Sorted by citations

Items 201–300 of 391

Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy
Wong‐Brown, M. W., van der Westhuizen, A., & Bowden, N. A. (2022) · BMC Cancer · doi:10.1186/s12885-022-09197-w · Cited by 20
Epigenetic Drugs and Their Immune Modulating Potential in Cancers
Liang, Y., & Turcan, Ş. (2022) · Biomedicines · doi:10.3390/biomedicines10020211 · Cited by 19
Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer
Yan, B., Yin, F., WANG, Q., Zhang, W., & LI, L. (2016) · Oncology Letters · doi:10.3892/ol.2016.4608 · Cited by 19
Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma
Fischer, C. D. C., Hu, Y., Morreale, M. T., Lin, W. Y., Wali, A., Thakar, M., Karunasena, E., Sen, R., Cai, Y., Murphy, L. M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25056 · Cited by 19
DNA methyltransferase inhibitors in hematological malignancies and solid tumors
Wenger, V., Garcia‐Manero, G., Zeiser, R., & Lübbert, M. (2025) · International Journal of Cancer · doi:10.1002/ijc.70197 · Cited by 18
Inhibition of DNMTs increases neoantigen-reactive T-cell toxicity against microsatellite-stable colorectal cancer in combination with radiotherapy
Huang, K. C., Ke, T., Lai, C.-Y., Hong, W.-Z., Chang, H.-Y., Lee, C., Wu, C.-H., Chiang, S., Liang, J., Chen, J.-Y., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116958 · Cited by 18
The tubal epigenome – An emerging target for ovarian cancer
Reavis, H. D., & Drapkin, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107524 · Cited by 20
Epigenetic Therapies in Melanoma—Targeting DNA Methylation and Histone Modification
Țigu, A. B., Ivancuta, A., Uhl, A., Sabo, A. C., Nistor, M., Mureșan, X. M., Cenariu, D., Timis, T., Diculescu, D. M., & Gulei, D. (2025) · Biomedicines · doi:10.3390/biomedicines13051188 · Cited by 17
G Protein-Coupled Estrogen Receptor Correlates With Dkk2 Expression and Has Prognostic Impact in Ovarian Cancer Patients
Fraungruber, P., Kaltofen, T., Heublein, S., Kühn, C., Mayr, D. C., Burges, A., Mahner, S., Rathert, P., Jeschke, U., & Trillsch, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.564002 · Cited by 18
Tackling drug resistance in ovarian cancer with epigenetic targeted drugs
Zhao, L., Guo, H., Chen, X., Zhang, W., He, Q., Ding, L., & Yang, B. W. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175071 · Cited by 17
Compartmentation of Metabolites in Regulating Epigenomes of Cancer
Zhao, Z., Wang, L., & Di, L. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00051 · Cited by 18
Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma
Budden, T., van der Westhuizen, A., & Bowden, N. A. (2018) · BMC Cancer · doi:10.1186/s12885-018-4010-9 · Cited by 17
Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells
Momeny, M., Eyvani, H., Barghi, F., Ghaffari, S. H., Javadikooshesh, S., Jamadi, R. H., Esmaeili, F., Alishahi, Z., Zaghal, A., Bashash, D., et al. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000681 · Cited by 16
Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer
Soto, J. A., Rodríguez‐Antolín, C., Vera, O., Pernía, O., Esteban‐Rodríguez, I., Diestro, M. D., Benitez, J. J., Sánchez‐Cabo, F., Álvarez-Gallego, R., de Castro, J., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01149-8 · Cited by 17
The promise of methylation on beads for cancer detection and treatment
Guzzetta, A. A., Pisanic, T. R., Sharma, P., Yi, J. M., Stark, A., Wang, T., & Ahuja, N. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.943665 · Cited by 17
Novel Approaches in Ovarian Cancer Research against Heterogeneity, Late Diagnosis, Drug Resistance, and Transcoelomic Metastases
Erol, A., Niemira, M., & Kretowski, A. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112649 · Cited by 19
Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure
Hu, J., Wang, X., Chen, F., Ding, M., Dong, M., Yang, W., Yin, M., Wu, J., Zhang, L., Fu, X., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.687374 · Cited by 16
Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation
Liu, J., Min, S., Kim, D., Park, J., Park, E., Koh, Y., Shin, D.-Y., Kim, T. K., Byun, J. M., Yoon, S., et al. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01493-x · Cited by 17
Is the pharmaceutical industry’s preoccupation with the monotherapy drug model stifling the development of effective new drug therapies?
Cock, I. E. (2018) · Inflammopharmacology · doi:10.1007/s10787-018-0488-7 · Cited by 16
CDH1 , DLEC1 and SFRP5 Methylation Panel As a Prognostic Marker for Advanced Epithelial Ovarian Cancer
Lin, H.-W., Fu, C., Chang, M., Lu, T., Lin, H.-P. P., Chiang, Y., Chen, C., & Cheng, W. (2018) · Epigenomics · doi:10.2217/epi-2018-0035 · Cited by 16
Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors
Steinbügl, M., Nemes, K., Johann, P. D., Kröncke, T. J., Tüchert, S., Gil‐da‐Costa, M. J., Ebinger, M., Schüller, U., Sehested, A. M., Hauser, P., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29267 · Cited by 16
Epigenetic modification and tumor immunity: Unraveling the interplay with the tumor microenvironment and its therapeutic vulnerability and implications
Zheng, H., Hua, Y., Yang, S., Liu, V., Huang, N., Li, J., Kleeff, J. H., Liao, Q., & Liu, Q. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217587 · Cited by 15
Development of TRAIL Resistance by Radiation-Induced Hypermethylation of DR4 CpG Island in Recurrent Laryngeal Squamous Cell Carcinoma
Lee, J. C., Lee, W. H., Min, Y. J., Cha, H. J., Han, M. W., Chang, H. W., Kim, S. A., Sh, C., Kim, S. Y., & Kim, S. Y. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.12.016 · Cited by 16
Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples
Stewart, D. J., Nunez, M. I., Jelı́nek, J., Hong, D. S., Gupta, S. K., Aldaz, C. M., Issa, J. J., Kurzrock, R., & Wistuba, I. I. (2014) · Clinical Epigenetics · doi:10.1186/1868-7083-6-13 · Cited by 15
Endometriosis and ovarian cancer risk, an epigenetic connection
Brunty, S., Mitchell, B. L., Zgheib, N. B., & Santanam, N. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2449 · Cited by 15
Epigenetic Targeting of Platinum Resistant Testicular Cancer
Sonnenburg, D., Spinella, M. J., & Albany, C. (2016) · Current Cancer Drug Targets · doi:10.2174/1568009616666151222150359 · Cited by 15
The role of membrane transporters in ovarian cancer chemoresistance and prognosis
Cerovská, E., Elsnerová, K., Václavíková, R., & Souček, P. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1332179 · Cited by 15
Brush-shaped RAFT polymer micelles as nanocarriers for a ruthenium (II) complex photodynamic anticancer drug
Wang, D., Wang, J., Huang, H., Zhao, Z., Gunatillake, P. A., & Hao, X. (2019) · European Polymer Journal · doi:10.1016/j.eurpolymj.2019.01.074 · Cited by 15
The role of DNA methylation in ovarian cancer chemoresistance: A narrative review
Song, K., & Artibani, M. (2023) · Health Science Reports · doi:10.1002/hsr2.1235 · Cited by 12
Methylation of DNA repair genes and the efficacy of DNA targeted anticancer treatment
Julsing, J. R., & Peters, G. J. (2014) · Oncology Discovery · doi:10.7243/2052-6199-2-3 · Cited by 14
EGFL7 and RASSF1 promoter hypermethylation in epithelial ovarian cancer
Rattanapan, Y., Korkiatsakul, V., Kongruang, A., Chareonsirisuthigul, T., Rerkamnuaychoke, B., Wongkularb, A., & Wilailak, S. (2018) · Cancer Genetics · doi:10.1016/j.cancergen.2018.04.117 · Cited by 14
Epigenetic therapy can inhibit growth of ovarian cancer cells and reverse chemoresistant properties acquired from metastatic omentum
Sookram, J., Zheng, A., Linden, K. M., Morgan, A. B., Brown, S. A., & Ostrovsky, O. (2019) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12800 · Cited by 14
Epigenome-Wide Histone Acetylation Changes in Peripheral Blood Mononuclear Cells in Patients with Type 2 Diabetes and Atherosclerotic Disease
Bompada, P., Gonçalves, I., Wu, C., Gao, R., Sun, J., Mir, B. A., Luan, C., Renström, E., Groop, L., Weng, J., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9121908 · Cited by 15
A new strategy for overcoming drug resistance in liver cancer: Epigenetic regulation
Su, X., Li, Y., Ren, Y., Cao, M., Yang, G., Luo, J., Hu, Z., Deng, H., Deng, M., Liu, B., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116902 · Cited by 14
Ovarian Cancer and Drug Resistance
Sato, S., & Itamochi, H. (2015) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-014-0111-x · Cited by 13
Expression of resistance gene and prognosis of chemotherapy in primary epithelial ovarian cancer
Yang, F., Gao, B., Chen, W., Du, E., Liang, Y., Hu, X., & Yang, X. (2018) · Medicine · doi:10.1097/md.0000000000012364 · Cited by 13
Expression profiling of DNA methyl transferase I (DNMT1) and efficacy of a DNA-hypomethylating agent (decitabine) in combination with chemotherapy in osteosarcoma
Chaiyawat, P., Sirikaew, N., Budprom, P., Klangjorhor, J., Phanphaisarn, A., Teeyakasem, P., Settakorn, J., & Pruksakorn, D. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100321 · Cited by 13
Resistance to Platinum-Based Cancer Drugs: a Special Focus on Epigenetic Mechanisms
Mora, Y., Reyes, M. E., Zanella, L., Mora, B. L., Buchegger, K., Ili, C., & Brebi, P. (2021) · Pharmacogenomics · doi:10.2217/pgs-2021-0020 · Cited by 13
Gene methylation of human ovarian carcinoma stromal progenitor cells promotes tumorigenesis
Ho, C., Shih, D., Hsiao, C.-C., Huang, S., Chang, S.-F., & Cheng, W. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0722-7 · Cited by 13
A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS ‐102 in irinotecan‐refractory metastatic colorectal cancer patients
Lee, V., Parkinson, R. M., ZAHURAK, M. L., Cope, L., Cercek, A., Verheul, H. M. W., Gootjes, E. C., Lenz, H. J., Iqbal, S., Jones, P. A., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34845 · Cited by 13
Epigenetic regulation in ovarian cancer
Thị, H. V., Ngo, A.-D., & Chu, D. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.03.006 · Cited by 12
Epigenetic Modulation of Estrogen Receptor Signaling in Ovarian Cancer
Skrzypczak, M., Wolińska, E., Adaszek, Ł., Ortmann, O., & Treeck, O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010166 · Cited by 12
Prognostic value of MLH1 promoter methylation in male patients with esophageal squamous cell carcinoma
Wu, D., Chen, X., Xu, Y., Wang, H., Yu, G., Jiang, L., Hong, Q., & Duan, S. (2017) · Oncology Letters · doi:10.3892/ol.2017.5759 · Cited by 12
Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape
Zou, X., Zhao, Y., Liang, X., Wang, H., Zhu, Y., & Shao, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641937 · Cited by 12
The Bitter Side of Epigenetics: Variability and Resistance to Chemotherapy
Hajji, N., García-Domínguez, D. J., Hontecillas‐Prieto, L., O’Neill, K., de Álava, E., & Syed, N. (2018) · Epigenomics · doi:10.2217/epi-2017-0112 · Cited by 13
A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent
Thakar, M., Hu, Y., Morreale, M. T., Lerner, L., Lin, W. Y., Sen, R., Cai, Y., Karunasena, E., Thakar, M., Saggi, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199130 · Cited by 12
Cross platform analysis of methylation, miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology
Poynter, J. N., Bestrashniy, J., Silverstein, K. A. T., Hooten, A. J., Lees, C. J., Ross, J. A., & Tolar, J. (2015) · BMC Cancer · doi:10.1186/s12885-015-1796-6 · Cited by 12
Developmental DNA methyltransferase inhibitors in the treatment of gynecologic cancers
Dueñas‐González, A., Medina‐Franco, J. L., Chávez-Blanco, A. D., Domínguez-Gómez, G., & Gortari, E. F. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1118053 · Cited by 12
Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study
Wang, H., Wang, Z., Wang, Z., Li, X., Li, Y., Yan, N., Wu, L., Liang, Y., Wu, J., Song, H., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1016-8 · Cited by 11
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
Nguyen, L. L., Watson, Z. L., Ortega, R., Woodruff, E. R., Jordan, K. R., Iwanaga, R., Yamamoto, T. M., Bailey, C. A., To, F., Jeong, A. D., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0613 · Cited by 11
Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review
Chovanec, M., Taza, F., Kalra, M., Hahn, N. M., Nephew, K. P., Spinella, M. J., & Albany, C. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0546-x · Cited by 11
Self-citation
Everolimus following 5-aza-2-deoxycytidine is a promising therapy in paclitaxel-resistant clear cell carcinoma of the ovary.
Ho, C., Lee, F., Huang, S., & Cheng, W. (2018) · PubMed Central · Cited by 11
SPIRE – combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial
Crabb, S. J., Danson, S. J., Catto, J. W. F., McDowell, C., Lowder, J. N., Caddy, J., Dunkley, D., Rajaram, J., Ellis, D., Hill, S., et al. (2018) · Trials · doi:10.1186/s13063-018-2586-7 · Cited by 11
New strategies for applying targeted therapies to adrenocortical carcinoma
Mohan, D. R., Lerário, A. M., Finco, I., & Hammer, G. D. (2019) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2019.07.006 · Cited by 11
Epigenetically programmed resistance to chemo- and immuno-therapies
Walker, R. R., Rentia, Z., & Chiappinelli, K. B. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2022.12.001 · Cited by 13
Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
Wang, Y., Situ, X., Cárdenas, H., Siu, E., Alhunayan, S. A., Keathley, R., Tanner, E. J., Wei, J., Tan, Y., Dessai, C. V. P., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2368 · Cited by 10
Self-citation
Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations
Valdez, B. C., Tsimberidou, A. M., Yuan, B., Baysal, M. A., Chakraborty, A., Andersen, C. R., & Andersson, B. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179241 · Cited by 12
Role of Circulating miRNAs in Therapeutic Response in Epithelial Ovarian Cancer: A Systematic Revision
Ravegnini, G., Iaco, P. D., Gorini, F., Dondi, G., Klooster, I., Crescenzo, E. D., Bovicelli, A., Hrelia, P., Perrone, A. M., & Angelini, S. (2021) · Biomedicines · doi:10.3390/biomedicines9101316 · Cited by 10
Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors
Stewart, D. J., Nunez, M. I., Jelı́nek, J., Hong, D. S., Gupta, S. K., Issa, J. J., Wistuba, I. I., & Kurzrock, R. (2014) · Clinical Epigenetics · doi:10.1186/1868-7083-6-2 · Cited by 10
Factors affecting the persistence of drug-induced reprogramming of the cancer methylome
Bell, J. S. K., Kagey, J. D., Barwick, B. G., Dwivedi, B., McCabe, M. T., Kowalski, J., & Vertino, P. M. (2016) · Epigenetics · doi:10.1080/15592294.2016.1158364 · Cited by 11
A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet
Cottrill, H. M., Cason, S., Caroen, S. Z., Oronsky, B. T., & Donaldson, E. S. (2018) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709618760080 · Cited by 10
Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators
Rauscher, S., Greil, R., & Geisberger, R. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009620666210108102723 · Cited by 10
Carboplatin and decitabine loaded lipid-coated albumin nanoparticles for an efficient treatment of platinum-resistant ovarian cancer
Esim, O., Hasçiçek, C., Gedik, M. E., Günaydın, G., & Dogan, A. L. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103801 · Cited by 10
Associating Immunotherapy and Targeted Therapies: Facts and Hopes
Ladoire, S., Rébé, C., & Ghiringhelli, F. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1184 · Cited by 10
Pre-Operative Decitabine in Colon Cancer Patients: Analyses on WNT Target Methylation and Expression
Linnekamp, J. F., Kandimalla, R., Fessler, E., de Jong, J. H., Rodermond, H. M., van Bochove, G. G. W., The, F. O., Punt, C. J. A., Bemelman, W. A., van de Ven, A. W. H., et al. (2021) · Cancers · doi:10.3390/cancers13102357 · Cited by 9
CpG methylation increases the DNA binding of 9-aminoacridine carboxamide Pt analogues
Kava, H. W., & Murray, V. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.08.011 · Cited by 9
Identifying CpG sites with different differential methylation frequencies in colorectal cancer tissues based on individualized differential methylation analysis
Yan, H., He, J., Guan, Q., Cai, H., Zhang, L., Zheng, W., Qi, L., Zhang, S., Liu, H., Li, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17647 · Cited by 9
Modulation of the Endothelin System in Colorectal Cancer Liver Metastasis: Influence of Epigenetic Mechanisms?
Mahdi, M. R., Georges, R. B., Ali, D. M., Bedeer, R. F., Eltahry, H., Gabr, A., & Berger, M. R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00180 · Cited by 9
Targeting Epigenetic Dependencies in Solid Tumors: Evolutionary Landscape Beyond Germ Layers Origin
Citron, F., & Fabris, L. (2020) · Cancers · doi:10.3390/cancers12030682 · Cited by 9
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Zou, R., Jiang, Q., Luo, X., Chen, M., Yuan, L., & Yao, L. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03230-3 · Cited by 9
Key actors in cancer therapy: epigenetic modifiers
Akar, R. O., Selvi, S., Ulukaya, E., & Aztopal, N. (2019) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1903-39 · Cited by 9
EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Nguyen, L. L., Watson, Z. L., Ortega, R., Woodruff, E. R., Jordan, K. R., Iwanaga, R., Yamamoto, T. M., Bailey, C. A., To, F., Lin, S., et al. (2024) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0067 · Cited by 9
Striking the right balance with type I interferon signalling in cancer
Chadwick, T. B., So, J., Hertzog, P. J., Haynes, N. M., & Parker, B. S. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00915-1 · Cited by 14
Insight into the Basic Mechanisms and Various Modulation Strategies Involved in Cancer Drug Resistance
Yadav, D., Rao, G. S. N. K., Paliwal, D., Singh, A., & Shadab, S. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230508110258 · Cited by 8
Ovarian solid tumors: Current treatment and recent developments using stimuli-responsive polymers: A systemic review
Santhosh, S., Nanjan, M. J., & Chandrasekar, M. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.03.018 · Cited by 8
Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy
Cho, Y., Milane, L. S., & Amiji, M. M. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1602605 · Cited by 7
Downregulation of promoter methylation gene PRDM5 contributes to the development of tumor proliferation and predicts poor prognosis in gastric cancer
Teng, J.-J., Zhao, W., Zhang, X., Zhao, D., Qiu, X., Chen, X., & Yang, L. (2021) · Journal of Cancer · doi:10.7150/jca.59998 · Cited by 8
Biological role and clinical implications of homeobox genes in serous epithelial ovarian cancer
Miller, K., Patel, J. N., Ganapathi, M. K., Tait, D. L., & Ganapathi, R. N. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.03.004 · Cited by 8
Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?
Moreta-Moraleda, C., Queralt, C., Vendrell-Ayats, C., Forcales, S. V., & Martinez‐Balibrea, E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106924 · Cited by 7
Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge
van der Westhuizen, A., Lyle, M. K., Graves, M. C., Zhu, X., Wong, J. W. H., Cornall, K., Ren, S. P., Pugliese, L., Levy, R., Majid, A., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0128 · Cited by 7
Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor Cells
Gerton, T. J., Green, A., Campisi, M., Chen, M., Gjeci, I., Mahadevan, N. R., Lee, C. A. A., Mishra, R., Vo, H. V., Haratani, K., et al. (2023) · Cancers · doi:10.3390/cancers15164128 · Cited by 8
Immune-related gene methylation prognostic instrument for stratification and targeted treatment of ovarian cancer patients toward advanced 3PM approach
Jia, W., Li, N., Wang, J., Gong, X., Ouédraogo, S. Y., Wang, Y., Zhao, J., Grech, G., Chen, L., & Zhan, X. (2024) · The EPMA Journal · doi:10.1007/s13167-024-00359-3 · Cited by 7
Systematic Investigation of DNA Methylation Associated With Platinum Chemotherapy Resistance Across 13 Cancer Types
Sun, R., Du, C.-C., Li, J., Zhou, Y.-H., Xiong, W., Xiang, J.-J., Liu, J.-H., Xiao, Z.-G., Fang, L., & Li, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.616529 · Cited by 7
UHRF1 Deficiency Inhibits Alphaherpesvirus through Inducing RIG-I-IRF3-Mediated Interferon Production
Wang, M., Song, J., Gao, C., Yu, C., Qin, C., Lang, Y., Xu, A., Liu, Y., Feng, W.-H., Tang, J., et al. (2023) · Journal of Virology · doi:10.1128/jvi.00134-23 · Cited by 7
Dysregulated expression of homeobox family genes may influence survival outcomes of patients with epithelial ovarian cancer: analysis of data from The Cancer Genome Atlas
Eoh, K. J., Kim, H. J., Lee, J., Nam, E. J., Kim, S., Kim, S. W., & Kim, Y. T. (2017) · Oncotarget · doi:10.18632/oncotarget.19771 · Cited by 7
Cancer Epigenetics
Takeshima, H., Yamada, H., & Ushijima, T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00005-3 · Cited by 7
Everolimus combined with 5-aza-2-deoxycytidine generated potent anti-tumor effects on ovarian clear cell cancer stem-like/spheroid cells by inhibiting the COL6A3-AKT-mTOR pathway.
Ho, C., Lee, F., Yen, T., Huang, S., & Cheng, W. (2022) · PubMed Central · Cited by 7
Differential Regulation of Methylation-Regulating Enzymes by Senescent Stromal Cells Drives Colorectal Cancer Cell Response to DNA-Demethylating Epi-Drugs
Agrawal, K., Das, V., Kudlová, N., Gurský, J., Džubák, P., & Hajdúch, M. (2018) · Stem Cells International · doi:10.1155/2018/6013728 · Cited by 7
Comprehensive Analysis of DNA Methyltransferases Expression in Primary and Relapsed Ovarian Carcinoma
Papakonstantinou, Ε., Pappa, I., Georgios, A., Adonakis, G., Maroulis, I. C., & Tzelepi, V. (2023) · Cancers · doi:10.3390/cancers15204950 · Cited by 6
Emerging applications of hypomethylating agents in the treatment of glioblastoma (Review)
Silva-Hurtado, T. J., Inocencio, J. F., & Yong, R. L. M. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2757 · Cited by 6
Epigenetics in Ovarian Cancer: A Review of Current Knowledge and Future Perspectives
Dedes, N., Liontos, M., Haidopoulos, D. A., Zagouri, F., Angelou, K., Svarna, A., Michas, A., Aravantinou‐Fatorou, A., Andrikopoulou, Α., & Dimopoulos, M. A. (2025) · Biomedicines · doi:10.3390/biomedicines13112820 · Cited by 7
Epigenetics-Associated Risk Reduction of Hematologic Neoplasms in a Nationwide Cohort Study: The Chemopreventive and Therapeutic Efficacy of Hydralazine
Yang, B.-H., Lin, W.-Z., Chiang, Y., Chen, Y., Chung, C., Chien, W., & Shiau, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809014 · Cited by 6
Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice
Stiff, P. J., Mehrotra, S., Potkul, R. K., Banerjee, S., Walker, C. J., & Drakes, M. L. (2023) · Cancers · doi:10.3390/cancers15184541 · Cited by 6
DNA methylation characteristics associated with chemotherapy resistance in epithelial ovarian cancer
Duan, C., Yan, Z., Wu, C., Zhou, X., & Bao, W. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27212 · Cited by 6
Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases
Zhu, X., Yang, H., Lang, J., & Zhang, Y. (2019) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2019.06.015 · Cited by 6
Big data-based identification of methylated genes associated with drug resistance and prognosis in ovarian cancer
Yan, B., Xiong, C., Huang, F., Zhang, M., Mo, Y., & Bai, H. (2020) · Medicine · doi:10.1097/md.0000000000020802 · Cited by 6
Natural and Acquired Resistance to Cancer Therapies
Sikic, B. I. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00047-0 · Cited by 6
Epigenetic modifications and transgenerational inheritance in women victims of violence (EWVV)
Gemmati, D., Villanova, M., Scarpellini, F., Milani, D., Cecchi, R., Singh, A. V., Gaudio, R. M., & Tisato, V. (2025) · Current Zoology · doi:10.1093/eep/dvaf025 · Cited by 8
Molecular Determinants of Chemotherapy Resistance in Ovarian Cancer
Cooley, M., Fang, P., Fang, F., Nephew, K. P., & CHIEN, J. R. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.130 · Cited by 5
Self-citation
Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors
Alam, S., & Giri, P. K. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2023.152 · Cited by 5

Authors: Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P.
Affiliations: Indiana University Health (US)
Corresponding author: Matei, Daniela
Nephew, Kenneth P.
ORCID: Matei, Daniela
Fang, Fang
Shen, Changyu
Schilder, Jeanne
Zeng, Yan
Berry, William A.
Huang, Tim
Nephew, Kenneth P.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2012-04-30
Volume: 72
Issue: 9
Pages: 2197-2205
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-11-3909
PMC: PMC3700422
OpenAlex: W2151783390
Cited by: 390
References: 56
Citations by year: 2026: 20 · 2025: 11 · 2024: 27 · 2023: 23 · 2022: 21 · 2021: 33 · 2020: 21 · 2019: 38 · 2018: 36 · 2017: 33 · 2016: 35 · 2015: 39 · 2014: 32 · 2013: 18 · 2012: 3
FWCI: 34.25
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
IUScholarWorks (Indiana University) (submittedVersion)
Funders: U.S. Food and Drug Administration
National Cancer Institute (CA113001, R21CA133877, R01CA085289, U54CA113001, CA133877)
Topics: Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
Keywords: ovarian cancer, platinum resistance, decitabine, DNA demethylation, hypomethylating agents, carboplatin, progression-free survival, MLH1, RASSF1A, HOXA10, HOXA11, drug transporters, Wnt signaling, apoptosis, cytokine signaling pathways
MeSH terms: Decitabine, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms, Peritoneal Neoplasms, Carboplatin, Disease-Free Survival, DNA Methylation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epigenetic Resensitization to Platinum in Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks